Niagen Bioscience (NAGE) Liabilities from Discontinued Operations (2016 - 2017)
Niagen Bioscience (NAGE) posted quarterly Liabilities from Discontinued Operations of 215000.0 for Q4 2017, up 16.36% year-over-year from 184766.0 in Q4 2016, and little changed quarter-over-quarter from 215000.0 in Q3 2017.
Powered by 
Analysis
Niagen Bioscience (NAGE) Liabilities from Discontinued Operations (2016 - 2017) Analysis & Trends
Niagen Bioscience (NAGE) has reported Liabilities from Discontinued Operations for 2 consecutive years, with 215000.0 the latest figure, recorded in Q4 2017.
- In Q4 2017, Liabilities from Discontinued Operations rose 16.36% year-over-year to 215000.0; the TTM figure through Dec 2017 stood at 215000.0 (up 16.36% YoY), while the FY2017 annual figure was 215000.0, up 16.36% from the prior year.
- Liabilities from Discontinued Operations was little changed at 215000.0 in Q4 2017 per NAGE's latest filing, from 215000.0 in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at 215000.0 in Q3 2017 and bottomed at 184766.0 in Q4 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 30, 2017 | 215,000.00 |
| Sep 30, 2017 | 215,000.00 |
| Dec 31, 2016 | 184,766.00 |